Severe Legionnaires' disease refractory to azithromycin: Are quinolones superior to macrolides?
Abstract
Legionnaires' disease is typically treated with either a macrolide or fluoroquinolone. Antimicrobial sensitivity testing of clinical samples is not routinely done because Legionella is difficult to culture. Controlled trials to suggest non-inferiority of either class are limited. We present a case of a 43-year-old immunosuppressed man with severe Legionella pneumonia whose clinical course was complicated by persistent fevers, acute metabolic encephalopathy, septic shock, rhabdomyolysis, and acute kidney injury while on azithromycin. He rapidly improved after a switch to levofloxacin. The current guidelines recommend either using a quinolone or macrolide for Legionella pneumonia. However, there are conflicting data suggestive of a benefit of quinolones over macrolides. Our case prompts the question of optimal antibiotic choice in cases of severe Legionnaires' disease in immunocompromised patients and highlights the need for randomized controlled trials for further guidance.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.